Compare Marqeta Inc (MQ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Neurocrine Biosciences Inc — how do they compare? Marqeta Inc trades at $17.1 (market cap $1.82B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.9× Marqeta Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MQ | NBIX | |
|---|---|---|
Market Cap | $1.82B | $14.36B |
Volume | 1,126,466 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $20.32 | $185.50 |
52-Week Low | $15.04 | $123.10 |
Typical Hold Time | 44 Days | 23 Days |
Enterprise Value | $1.13B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $17.06, up 3.08% with a bullish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and revenue growth from $507M in 2024 to projected $677M in 2026. Recent partnerships with BVNK for stablecoin cards and Google for wallet expansion highlight strategic growth initiatives. However, valuation metrics remain elevated with a P/E of 189.56 and EV/EBITDA of 52.44 despite modest profitability margins.
MQ presents a mixed outlook with strong operational momentum but premium valuation. The stock offers growth potential through expanding payment partnerships and enterprise adoption, though faces risks from contract renewals in Q3 2026 and competitive pressure. Analyst consensus of $11.38 suggests caution despite recent bullish earnings revisions and institutional interest in the digital payments space.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
